Valuation: Lupin Limited

Market Cap 1,120B 11.69B 10.28B 9.59B 8.8B 16.48B 16.88B 114B 44.48B 554B 43.91B 42.95B 1,916B P/E 2027 *
24.4x
P/E 2028 * 24.1x
Enterprise Value 1,074B 11.22B 9.85B 9.2B 8.44B 15.8B 16.19B 109B 42.66B 532B 42.11B 41.19B 1,838B EV / Sales 2027 *
3.6x
EV / Sales 2028 * 3.32x
Free-Float
52.97%
Yield 2027 *
0.53%
Yield 2028 * 0.51%
1 day-0.98%
1 week+1.25%
Current month+0.24%
1 month+0.24%
3 months+5.30%
6 months+12.78%
Current year+14.86%
1 week 2,340.6
Extreme 2340.6
2,475
1 month 2,340.6
Extreme 2340.6
2,530
Current year 2,072.95
Extreme 2072.95
2,530
1 year 1,838.65
Extreme 1838.65
2,530
3 years 971.85
Extreme 971.85
2,530
5 years 583.05
Extreme 583.05
2,530
10 years 505
Extreme 505
2,530
Manager TitleAgeSince
Chief Executive Officer 58 2013-08-31
Director of Finance/CFO 61 2007-08-12
Compliance Officer - 2024-08-31
Director TitleAgeSince
Director/Board Member 52 2008-10-07
Director/Board Member 58 1996-12-31
Chairman 82 2017-08-10
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%+1.25%+22.27%+146.20% 11.69B
-0.87%+4.04%+58.60%+163.92% 1,079B
-0.45%+3.87%+57.95%+52.18% 640B
+0.04%+3.95%+37.69%+74.54% 465B
-0.72%+8.81%+39.38%+34.26% 353B
-0.50%+3.51%+36.97%+43.76% 301B
-0.91%+3.40%+17.71%+18.77% 271B
-0.72%+5.81%-2.55%-36.02% 228B
-1.39%+5.90%+27.70%+64.00% 209B
-1.18%+1.83%+16.20%+72.69% 165B
Average -0.47%+4.53%+31.19%+63.43% 372.14B
Weighted average by Cap. -0.50%+4.86%+41.86%+79.04%

Financials

2027 *2028 *
Net sales 298B 3.11B 2.74B 2.55B 2.34B 4.39B 4.5B 30.29B 11.84B 148B 11.69B 11.44B 510B 313B 3.26B 2.87B 2.68B 2.46B 4.6B 4.71B 31.74B 12.41B 155B 12.25B 11.99B 535B
Net income 45.84B 479M 421M 393M 360M 674M 691M 4.65B 1.82B 22.69B 1.8B 1.76B 78.42B 46.32B 484M 425M 397M 364M 681M 698M 4.7B 1.84B 22.92B 1.82B 1.78B 79.24B
Net Debt -45.91B -479M -421M -393M -361M -675M -692M -4.66B -1.82B -22.72B -1.8B -1.76B -78.54B -81.57B -852M -748M -699M -641M -1.2B -1.23B -8.28B -3.24B -40.37B -3.2B -3.13B -140B
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
26,021
Date Price Change Volume
26-07-30 2,439.85 -0.41% 49,547
26-07-29 ₹2,449.80 +2.30% 113,778
26-07-28 ₹2,394.70 -0.63% 4,928
26-07-27 ₹2,409.90 +1.71% 16,596
26-07-24 ₹2,369.45 -1.11% 10,680
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
37
Last Close Price
2,449.80INR
Average target price
2,488.68INR
Spread / Average Target
+1.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUPIN Stock